Announcing Wide-Ranging ZD4054 Phase III Development Program For Prostate Cancer Treatment

New Phase II data presented suggest that ZD4054, a novel compound in development for the treatment of men with Hormone Resistant Prostate Cancer (HRPC), could offer a promising improvement in overall survival in men with metastatic HRPC who were asymptomatic or mildly symptomatic for pain. Patients who received ZD4054 10mg once-daily experienced a 45 percent reduction in the risk of death compared to placebo (HR 0.55; 80 percent CI 0.41, 0.73). [click link for full article]

More: continued here

Filed under: Endocrinology on September 28th, 2007